Pharmacy Technician Certification Exams — Pharmacy Technician Certification Exam Review
1. Which of the following medications is indicated to treat hyperkalemia?
Answer: D
Lokelma is indicated to treat hyperkalemia.
Lokelma is a medication specifically designed to treat hyperkalemia, a condition characterized by elevated potassium levels in the blood. It works by binding potassium in the gastrointestinal tract and promoting its excretion.
A) Levoxyl
Levoxyl is a brand name for levothyroxine, a synthetic thyroid hormone used to treat hypothyroidism. It does not have any indication or mechanism related to the treatment of hyperkalemia, making it an incorrect choice.
B) Loperamide
Loperamide is an antidiarrheal medication that works by slowing down gut movement. It does not address potassium levels in the body and is not indicated for hyperkalemia, rendering this option incorrect.
C) Levetiracetam
Levetiracetam is an anticonvulsant medication primarily used to treat seizures. It has no role in managing potassium levels or treating hyperkalemia, thus making this option incorrect.
D) Lokelma
Lokelma is specifically indicated for the treatment of hyperkalemia. It effectively binds potassium in the gut, facilitating its removal from the body and lowering serum potassium levels, making this option correct.
Conclusion
Lokelma is the only medication listed that is specifically indicated for the treatment of hyperkalemia, effectively addressing the condition through its mechanism of action. All other options do not have any relevance to hyperkalemia and are intended for different medical conditions. Therefore, Lokelma stands out as the definitive correct choice among the options provided.
2. Lovastatin is used to lower:
Answer: A
Lovastatin is used to lower cholesterol.
Lovastatin is a medication that specifically targets and helps reduce cholesterol levels in the body, making it effective in managing dyslipidemia and preventing cardiovascular disease.
A) cholesterol.
This option is correct. Lovastatin is classified as a statin, a type of drug that inhibits HMG-CoA reductase, an enzyme involved in the production of cholesterol in the liver. By lowering cholesterol levels, lovastatin reduces the risk of heart disease and stroke.
B) blood pressure.
This option is incorrect. Lovastatin does not primarily affect blood pressure levels. While managing cholesterol can have an indirect positive impact on cardiovascular health, lovastatin is not indicated for the treatment of hypertension.
C) blood glucose.
This option is incorrect. Lovastatin is not designed to lower blood glucose levels. It does not have direct effects on glucose metabolism and is not utilized in the management of diabetes or hyperglycemia.
D) acid reflux.
This option is incorrect. Lovastatin is not used to treat acid reflux or gastroesophageal reflux disease (GERD). Its therapeutic action is aimed at cholesterol reduction rather than gastrointestinal conditions.
Conclusion
In summary, lovastatin's primary function is to lower cholesterol, which is crucial for reducing the risk of cardiovascular events. The other options, including blood pressure, blood glucose, and acid reflux, do not relate to the pharmacological action of lovastatin, confirming that option A is the definitive correct choice.
Answer: B
The pharmacy technician is most likely to receive a rejection message for therapeutic duplication.
When a patient has been prescribed both amlodipine and diltiazem, which are both calcium channel blockers, this raises a concern for therapeutic duplication. This means that the combination of these medications could lead to an increased risk of side effects without adding significant benefit.
A) Prior authorization required
This option is unlikely to be the correct rejection message in this scenario because prior authorization typically applies to medications that are expensive or require specific clinical criteria for coverage. Since both amlodipine and diltiazem are commonly prescribed medications, they generally do not require prior authorization.
B) Therapeutic duplication
This is the correct rejection message. Therapeutic duplication occurs when a patient is prescribed two or more medications that serve the same purpose or have similar effects, which can increase the risk of adverse effects. In this case, both amlodipine and diltiazem work as calcium channel blockers, leading the pharmacy system to flag this potential issue.
C) NDC not covered
This rejection message would indicate that the specific National Drug Code (NDC) for the prescribed medication is not covered by the patient's insurance plan. However, since both amlodipine and diltiazem are standard medications, it is improbable that either would be denied coverage based solely on their NDCs.
D) Refill too soon
This message pertains to situations where a patient attempts to refill a medication before the appropriate time frame has elapsed. In this case, the patient is not refilling but rather filling a new prescription for a different medication, making this rejection message irrelevant.
Conclusion
The rejection message for therapeutic duplication is the most appropriate response due to the simultaneous prescriptions of amlodipine and diltiazem, both of which have overlapping therapeutic effects. Other options do not accurately reflect the situation, as they pertain to different issues that are not present in this case. Thus, option B is definitively the correct choice.
4. Which of the following products is most likely to be rejected by a reverse distributor?
Answer: A
An expired investigational medication
An expired investigational medication is most likely to be rejected by a reverse distributor due to its uncertain safety and efficacy profile beyond its expiration date.
A) An expired investigational medication
This option is correct because investigational medications are typically subject to strict regulations and oversight. Once they expire, their safety and effectiveness are no longer guaranteed, making them unsuitable for redistribution or reuse, which aligns with the reverse distributor's criteria for accepting products.
B) An unopened, expired stock bottle in the original manufacturer packaging
This option is incorrect as unopened, expired stock bottles in their original packaging may still be accepted by reverse distributors. These products are often still in a condition that allows for potential return to the manufacturer or for proper disposal, especially if they have not been opened or tampered with.
C) An expired topical product
This option is also incorrect because expired topical products may still be considered for return if they remain sealed and in their original packaging. The safety of topical products can sometimes be less critical compared to investigational drugs, leading to differing acceptance criteria.
D) A refrigerated medication that has already passed its printed expiration date
This option is incorrect since refrigerated medications, while needing careful handling, may still be accepted if they have been stored properly before expiring. Their acceptance largely depends on specific distributor policies and the nature of the medication itself.
Conclusion
The choice of an expired investigational medication is definitive as it poses the highest risk regarding safety and efficacy, which is critical for reverse distributors. Other options, while expired, may still be viable for return or disposal, reflecting the nuanced criteria used in the industry.
5. The therapeutic equivalence designation AB indicates that:"""""""
Answer: B
Drug products meet bioequivalence requirements.
The therapeutic equivalence designation AB indicates that the drug products are considered therapeutically equivalent and meet the necessary bioequivalence standards established by regulatory authorities.
A) bioequivalence problems have been identified.
This option is incorrect because the AB designation specifically signifies that no bioequivalence problems have been identified. Instead, it confirms that the products are equivalent in terms of therapeutic effects.
B) drug products meet bioequivalence requirements.
This option is correct as the AB designation denotes that the drug products in question have successfully met the bioequivalence requirements. It indicates that these products can be expected to have the same clinical effect and safety profile when administered to patients.
C) there is insufficient data to confirm bioequivalence.
This option is incorrect because it suggests a lack of data, which contradicts the AB designation. The designation is only given when sufficient data is available to confirm that the products meet bioequivalence standards.
D) new information has raised questions about bioequivalence.
This option is incorrect as the AB designation does not imply any doubts or questions regarding bioequivalence. Instead, it indicates established equivalence based on adequate evidence.
Conclusion
The correct answer, B, clearly defines the essence of the AB designation, confirming that the drug products meet bioequivalence requirements. All other options misinterpret the designation, either implying issues or insufficient data, which is contrary to what the AB designation represents. Thus, B stands out as the only accurate choice.
Answer: C
The total initial dose for a patient weighing 185 lb is 420 mg.
To calculate the total initial dose, we first convert the patient's weight from pounds to kilograms. Since 1 pound is approximately 0.453592 kilograms, a patient weighing 185 lb is approximately 83.91 kg. Multiplying this weight by the dosage of 5 mg/kg results in a total dose of about 420 mg.
A) 81.4
This option is incorrect. A dose of 81.4 mg would not be sufficient for a patient weighing 185 lb, as the calculation based on the weight indicates a higher required dosage.
B) 185
This option is also incorrect. A total dose of 185 mg does not align with the calculated requirement based on the patient's weight and the prescribed dosage of 5 mg/kg.
C) 420
This option is correct. The calculation shows that a patient weighing 185 lb, which converts to approximately 83.91 kg, requires a total initial dose of 420 mg when applying the dosage of 5 mg/kg.
D) 925
This option is incorrect. A total dose of 925 mg exceeds the calculated requirement for a patient of this weight, making it an inappropriate choice based on the given dosage guidelines.
Conclusion
The correct answer is 420 mg, as derived from converting the patient's weight from pounds to kilograms and applying the dosage of 5 mg/kg. All other options fail to meet the necessary dosage requirement based on the patient's actual weight, confirming that 420 mg is the only valid choice.
Answer: D
Spironolactone and potassium can lead to hyperkalemia.
The concurrent use of spironolactone, a potassium-sparing diuretic, with potassium supplements significantly increases the risk of hyperkalemia due to the potential for excessive potassium retention in the body.
A) Furosemide and amlodipine
This combination does not pose a risk for hyperkalemia. Furosemide is a loop diuretic that promotes potassium excretion, while amlodipine is a calcium channel blocker that does not affect potassium levels significantly.
B) Amlodipine and spironolactone
While spironolactone can increase potassium levels, amlodipine does not contribute to hyperkalemia. However, the risk of hyperkalemia mainly arises from spironolactone, making this combination less risky than spironolactone with potassium.
C) Potassium and furosemide
This combination is unlikely to cause hyperkalemia since furosemide leads to the excretion of potassium. Instead, adding potassium to furosemide could potentially counteract the potassium loss rather than cause an increase.
D) Spironolactone and potassium
This combination is particularly concerning as both medications can raise serum potassium levels. Spironolactone, being a potassium-sparing diuretic, retains potassium, and taking potassium supplements concurrently can lead to dangerously high potassium levels, resulting in hyperkalemia.
Conclusion
The combination of spironolactone and potassium is the most likely to result in hyperkalemia due to their synergistic effects on potassium retention. All other options either do not contribute to elevated potassium levels or actively promote potassium loss, thereby reducing the risk of hyperkalemia.
Answer: C
A medication serial number should have no more than 20 characters.
The Drug Supply Chain Security Act (DSCSA) stipulates that a medication serial number must be limited to a maximum of 20 characters to ensure proper tracking and identification throughout the supply chain.
A) 5
This option is incorrect because a medication serial number cannot be as short as 5 characters. Such a brief identifier would be insufficient for the unique identification required for pharmaceuticals in the supply chain.
B) 10
This option is also incorrect. While a 10-character serial number may provide some level of uniqueness, it does not comply with the DSCSA's requirement that allows for a longer identifier to facilitate better tracking and verification.
C) 20
This option is correct as it aligns with the requirements set by the DSCSA. A maximum of 20 characters for a medication serial number is established to ensure comprehensive identification and traceability of pharmaceuticals throughout the supply chain.
D) 50
This option is incorrect because allowing a medication serial number to be up to 50 characters would exceed the specifications outlined in the DSCSA. Such an extended length could lead to inefficiencies and complications in tracking and managing medications.
Conclusion
The correct answer is 20 characters, as mandated by the DSCSA, ensuring that medication serial numbers are sufficiently unique for effective supply chain management. All other options either fall short of the requirement or exceed the necessary limits, highlighting the importance of adhering to regulatory standards in pharmaceutical tracking.
Answer: A
Class I recall best fits this situation.
A Class I recall is warranted here because the situation presents a reasonable probability that the use of or exposure to the recalled product will cause serious adverse health consequences or death. Since acetaminophen and penicillin serve very different therapeutic purposes, the risk of serious harm is significant if a patient were to inadvertently take penicillin instead of acetaminophen.
A) Class I
Class I is the appropriate classification in this case, as it involves a situation where the error could lead to serious health risks. The mix-up of acetaminophen with penicillin poses a serious risk to patients, especially those with penicillin allergies, thereby necessitating immediate action.
B) Class II
Class II recalls are issued for products that may cause temporary or medically reversible adverse health consequences. However, given that the error involves potentially life-threatening medication, Class II does not accurately reflect the severity of this situation.
C) Class III
Class III recalls pertain to products that are unlikely to cause any adverse health consequences. Since the mix-up in this case involves a dangerous medication error, Class III is not applicable and fails to represent the seriousness of the risk involved.
D) Class IV
Class IV recalls are not a recognized classification in the context of medication recalls. Therefore, this option does not apply and does not contribute to an understanding of the recall's severity.
Conclusion
In summary, the correct classification for this recall is Class I due to the significant risk of serious health consequences associated with the error. All other options fail to capture the potential severity of the situation, as they either minimize the risk or do not exist within the standard recall categories.
Answer: B
Pregnant pharmacy staff members should avoid contact with crushed or broken tablets of finasteride.
Finasteride is a medication that can cause serious birth defects if handled by pregnant individuals. Therefore, it is essential for pregnant pharmacy staff members to avoid contact with this drug in its crushed or broken form.
A) furosemide.
Furosemide is a diuretic and does not have the same teratogenic effects associated with finasteride. While caution is always advised with any medication during pregnancy, furosemide is not specifically known to negatively impact fetal development in the same way that finasteride does.
B) finasteride.
Finasteride is known for its potential to cause significant birth defects, particularly affecting male fetuses. Pregnant women are advised to avoid exposure to this medication, especially in its crushed or broken state, to prevent any risk to fetal development.
C) fluoxetine.
Fluoxetine, an antidepressant, has been studied for its effects during pregnancy, but it does not carry the same level of risk for causing birth defects as finasteride. Therefore, while caution is warranted, it is not specifically advised to avoid contact with fluoxetine in the same manner as with finasteride.
D) famotidine.
Famotidine is a medication used to treat stomach issues and has not been linked to negative impacts on fetal development. Pregnant pharmacy staff do not require special precautions regarding famotidine that are as stringent as those required for finasteride.
Conclusion
Finasteride is the only medication listed that poses a significant risk of fetal development issues if handled by pregnant individuals. The other options, while they may require general caution, do not present the same level of risk and therefore do not necessitate the same avoidance measures. This emphasizes the importance of understanding the specific risks associated with certain medications during pregnancy.